Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Samantha R Oakes, Francois Vaillant, Elgene Lim, Lily Lee, Kelsey Breslin, Frank Feleppa, Siddhartha Deb, Matthew E Ritchie, Elena Takano, Teresa Ward, Stephen B Fox, Daniele Generali, Gordon K Smyth, Andreas Strasser, David CS Huang, Jane E Visvader, Geoffrey J Lindeman
Proceedings of the National Academy of Sciences of the United States of America | NATL ACAD SCIENCES | Published : 2012
We are grateful to K. Lowes, B. Pal, J. Corbin, M. Chapman, and the Royal Melbourne Hospital Tissue Bank staff for expert technical assistance; K. Stoev and A. Morcom for animal care; and S. Mihajlovic and E. Tsui for histology support. We thank P. Bouillet for discussions and Abbott Laboratories (S. Rosenberg, S. Elmore, and colleagues) and Genentech (W. Fairbrother) for providing ABT-737 and discussions. Primary tumor samples were provided by the Victorian Cancer Biobank (VCB). This work was supported by the Victorian Government through the Victorian Cancer Agency/Victorian Breast Cancer Research Consortium (J. E. V., G. J. L., and S. B. F.) and an Operational Infrastructure Support grant, the National Health and Medical Research Council Australia (NHMRC; to J. E. V., G. J. L., A. S., and D. C. S. H.) and the Australian Cancer Research Foundation. S.R.O. was supported by the NHMRC and the National Breast Cancer Foundation (NBCF); E. L. by the NHMRC and NBCF; L. L. by the NHMRC and the Cancer Therapeutics CRC; S. D. by the VCB; and A. S., D. C. S. H., J. E. V., and G. J. L. by NHMRC Research Fellowships.